骨髓增生异常综合征的基因表达与白血病转化风险
对100例骨髓增生异常综合征患者骨髓CD34+细胞进行转录组测序无监督聚类,识别出红系/巨核系(EMK)与未成熟祖细胞(IMP)两个亚型,IMP亚型生存显著更短且白血病转化仅见于该亚型,分类在183例独立队列中验证,并构建基于骨髓单个核细胞基因表达谱的预测模型。
要点
- 骨髓CD34+细胞转录组聚类识别EMK与IMP两个亚型,IMP亚型多信号通路上调、代谢与DNA修复通路下调。
- IMP亚型生存显著更短:单因素HR 5.0(95%CI 1.8-14,P=.002),多因素HR 4.9(95%CI 1.3-19,P=.02)。
- 白血病转化仅见于IMP亚型,分类在183例独立队列中验证,预测模型在114例测试集中成功预测临床结局。
核心结论
- 基于基因表达的分类具有生物学与临床相关性,可改善MDS的风险预测与治疗分层。
研究设计与样本
- 对100例骨髓增生异常综合征患者骨髓CD34+细胞进行转录组测序无监督聚类分析。
- 在183例独立队列中验证分类的预后意义。
- 构建基于未分选骨髓单个核细胞(BMMNC)基因表达谱的亚型预测模型,并在114例BMMNC样本测试集中评估。
主要发现
- 无监督聚类识别出两个亚组:EMK亚型以红系/巨核系相关基因表达增加为特征,IMP亚型以未成熟祖细胞相关基因上调为特征。
- 与EMK亚型相比,IMP亚型多种信号通路上调、若干代谢与DNA修复相关通路下调。
- IMP亚组生存显著更短:单因素分析HR 5.0(95%CI 1.8-14,P=.002),多因素分析HR 4.9(95%CI 1.3-19,P=.02)。
- 白血病转化仅局限于IMP亚组。
- 预测模型在114例BMMNC样本测试集中成功预测临床结局,将分类加入临床模型可改善患者结局预测。
关键数值与推荐
- IMP亚型 vs EMK亚型:单因素生存分析HR 5.0(95%CI 1.8-14,P=.002)。
- IMP亚型 vs EMK亚型:多因素生存分析HR 4.9(95%CI 1.3-19,P=.02)。
- 分类在183例独立队列中验证。
- 预测模型在114例BMMNC样本测试集中成功预测临床结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic disorders with a highly variable prognosis. To identify a gene expression-based classification of myelodysplasia with biological and clinical relevance, we performed a comprehensive transcriptomic analysis of myeloid neoplasms with dysplasia using transcriptome sequencing. Unsupervised clustering of gene expression data of bone marrow CD34+ cells from 100 patients identified 2 subgroups. The first subtype was characterized by increased expression of genes related to erythroid/megakaryocytic (EMK) lineages, whereas the second subtype showed upregulation of genes related to immature progenitor (IMP) cells. Compared with the first so-called EMK subtype, the IMP subtype showed upregulation of many signaling pathways and downregulation of several pathways related to metabolism and DNA repair. The IMP subgroup was associated with a significantly shorter survival in both univariate (hazard ratio [HR], 5.0; 95% confidence interval [CI], 1.8-14; P = .002) and multivariate analysis (HR, 4.9; 95% CI, 1.3-19; P = .02). Leukemic transformation was limited to the IMP subgroup. The prognostic significance of our classification was validated in an independent cohort of 183 patients. We also constructed a model to predict the subgroups using gene expression profiles of unfractionated bone marrow mononuclear cells (BMMNCs). The model successfully predicted clinical outcomes in a test set of 114 patients with BMMNC samples. The addition of our classification to the clinical model improved prediction of patient outcomes. These results indicated biological and clinical relevance of our gene expression-based classification, which will improve risk prediction and treatment stratification of MDS.
引用
- Shiozawa Y, Malcovati L, Gallì A, et al. Gene expression and risk of leukemic transformation in myelodysplasia. Blood. 2017. PMID: 29097382. doi:10.1182/blood-2017-05-783050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。